U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C34H53NO11
Molecular Weight 651.7847
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NALOXEGOL

SMILES

COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC=C)=C(O)C=C4

InChI

InChIKey=XNKCCCKFOQNXKV-ZRSCBOBOSA-N
InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1

HIDE SMILES / InChI

Molecular Formula C34H53NO11
Molecular Weight 651.7847
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

MOVANTIK (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic noncancer pain. It is being investigated for the treatment of constipation as a side effect of prescription opioid pain medicines.

CNS Activity

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.4 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
MOVANTIK
PubMed

PubMed

TitleDatePubMed
Incidence, prevalence, and management of opioid bowel dysfunction.
2001 Nov
Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden.
2007 Jul
New approaches to the treatment of opioid-induced constipation.
2008 Aug
A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
2013 Sep
Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation.
2015 Jul-Sep
Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain.
2015 Mar
Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
2016 Nov
Patents

Patents

Sample Use Guides

In Vivo Use Guide
The recommended MOVANTIK dosage is 25 mg once daily in the morning. If patients are not able to tolerate MOVANTIK, reduce the dosage to 12.5 mg once daily.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Oct 21 21:43:45 UTC 2019
Edited
by admin
on Mon Oct 21 21:43:45 UTC 2019
Record UNII
44T7335BKE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NALOXEGOL
DASH   INN   USAN   WHO-DD  
INN   USAN  
Official Name English
NALOXEGOL [WHO-DD]
Common Name English
NALOXEGOL [USAN]
Common Name English
AZ-13337019
Code English
NKTR-118
Code English
MORPHINAN-3,14-DIOL, 4,5-EPOXY-6-(3,6,9,12,15,18,21-HEPTAOXADOCOS-1-YLOXY)-17-(2-PROPEN-1-YL)-, (5.ALPHA.,6.ALPHA.)-
Systematic Name English
4,5.ALPHA.-EPOXY-6.ALPHA.-((3,6,7,12,15,18,21-HEPTAOXADOCOSYL)OXY)-17-(PROP-2-ENYL)MORPHINAN-3,14-DIOL
Systematic Name English
NALOXEGOL [MI]
Common Name English
NALOXEGOL [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175691
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
WHO-VATC QA06AH03
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
WHO-ATC A06AH03
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
NCI_THESAURUS C681
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
Code System Code Type Description
CAS
854601-70-0
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
RXCUI
1551777
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY RxNorm
ChEMBL
CHEMBL2219418
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
HSDB
854601-70-0
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
MERCK INDEX
M11770
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
INN
9434
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
NCI_THESAURUS
C97506
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
DRUG BANK
DB09049
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
EPA CompTox
854601-70-0
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
EVMPD
SUB126723
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
WIKIPEDIA
NALOXEGOL
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
PUBCHEM
56959087
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
IUPHAR
7539
Created by admin on Mon Oct 21 21:43:45 UTC 2019 , Edited by admin on Mon Oct 21 21:43:45 UTC 2019
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
MAJOR
EXCRETED UNCHANGED
In feces, ~ 68 % of radioactivity dose was found; 58 % of fecal radioactivity was characterized, with 16 % noted to be unchanged drug and remaining as metabolites.
FECAL
EXCRETED UNCHANGED
16 % of radioactivity dose was found in urine, with 10 % as unchanged drug and 6 % as metabolites.
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC